PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. said its allogeneic mesenchymal precursor cell therapy showed an overall survival rate of 75 percent compared to an expected 30 percent survival rate in its pediatric phase III trial in acute graft-vs.-host disease (aGVHD) at 100 days.
PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. said its allogeneic mesenchymal precursor cell therapy showed an overall survival rate of 75 percent compared to an expected 30 percent survival rate in its pediatric phase III trial in acute graft-vs.-host disease (aGVHD) at 100 days.
PERTH, Australia – Melbourne-based Medicines Development for Global Health (MDGH) became the first not for profit company to register a drug through the FDA's tropical disease priority review program.
PERTH, Australia – Melbourne-based Medicines Development for Global Health (MDGH) became the first not for profit company to register a drug through the FDA's tropical disease priority review program.
PERTH, Australia – Sydney-based Immutep Ltd. unveiled new data for its phase I immunotherapy study that showed a long-lasting and durable response and an overall response rate of 61 percent in a melanoma study combining its lead immunotherapy with Merck's anti-PD-1 therapy Keytruda (pembrolizumab).
